Dimensional Fund Advisors LP Grows Position in C4 Therapeutics, Inc. $CCCC

Dimensional Fund Advisors LP boosted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 49.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 442,518 shares of the company’s stock after buying an additional 146,038 shares during the quarter. Dimensional Fund Advisors LP’s holdings in C4 Therapeutics were worth $1,160,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Zacks Investment Management bought a new stake in shares of C4 Therapeutics in the third quarter worth approximately $29,000. Delta Investment Management LLC bought a new position in C4 Therapeutics during the fourth quarter valued at approximately $38,000. Virtu Financial LLC bought a new position in C4 Therapeutics during the fourth quarter valued at approximately $39,000. Acadian Asset Management LLC purchased a new stake in C4 Therapeutics in the first quarter worth approximately $43,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in C4 Therapeutics in the 3rd quarter worth approximately $43,000. Institutional investors own 78.81% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, C4 Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $7.75.

C4 Therapeutics Price Performance

NASDAQ:CCCC opened at $4.24 on Friday. The firm has a market capitalization of $521.65 million, a price-to-earnings ratio of -4.24 and a beta of 2.91. C4 Therapeutics, Inc. has a one year low of $1.69 and a one year high of $5.17. The business has a fifty day moving average price of $3.91 and a 200-day moving average price of $3.19.

C4 Therapeutics (NASDAQ:CCCC) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. C4 Therapeutics had a negative return on equity of 45.45% and a negative net margin of 289.44%.The company had revenue of $6.64 million for the quarter, compared to the consensus estimate of $4.00 million. On average, equities research analysts expect that C4 Therapeutics, Inc. will post -0.85 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.